March 29, 2018 09:11 AM EDT
R&D

Med­i­ci­No­va flops in PhII metham­phet­a­mine de­pen­dence tri­al, stock slips

Brittany Meiling

San Diego drug­mak­er Med­i­ci­No­va has flunked a mid-stage tri­al test­ing its lead drug can­di­date against metham­phet­a­mine de­pen­dence, send­ing the com­pa­ny’s stock quick­ly south in pre …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times